Daiichi Sankyo has been ordered to pay an 8% royalty rate on sales of its breast cancer therapy Enhertu by a Texas court, on top of an earlier award of $41.8 million in damages, in an ongoing ...

Seagen – which is heading for a $43 billion takeover by Pfizer – had also sought to increase damage award on the grounds that Daiichi Sankyo’s infringement of the patent was ‘wilful ...

The proceeds from the sale of shares held by Malvinder Singh will go towards part payment of the Rs 3,500-crore arbitral award to ... to Japanese pharma major Daiichi Sankyo.

An AstraZeneca and Daiichi Sankyo drug designed to replace chemotherapy was cleared by US regulators for broader use in late-stage breast cancer patients. The Food and Drug Administration ...